Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
1996-02-16
2009-10-27
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S145100, C424S172100
Reexamination Certificate
active
07608262
ABSTRACT:
A method of treating or preventing a cardiovascular and/or a cerebrovascular disorder in an individual is disclosed. Also disclosed is a method for treating and/or preventing a thrombotic disorder in an individual. Further disclosed is a method of decreasing plasma fibrinogen in an individual.
REFERENCES:
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5317019 (1994-05-01), Bender et al.
patent: 5436154 (1995-07-01), Barbanti
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5547979 (1996-08-01), Christensen
patent: 5656272 (1997-08-01), Le et al.
patent: 5698195 (1997-12-01), Le
patent: 5863531 (1999-01-01), Naughton et al.
patent: 260610 (1988-03-01), None
patent: 453898 (1991-10-01), None
patent: 486809 (1992-05-01), None
patent: 626389 (1994-11-01), None
patent: 2289218 (1995-11-01), None
patent: WO 91/15451 (1991-10-01), None
patent: WO 92/09203 (1992-06-01), None
patent: 9216553 (1992-10-01), None
patent: WO 92/16553 (1992-10-01), None
patent: WO 94/10990 (1994-05-01), None
patent: WO 95/03827 (1995-02-01), None
patent: WO 95/19957 (1995-07-01), None
patent: WO 96/21447 (1996-07-01), None
Squadrito, Ev. J. Pharmocology 237: 223-230, 1993.
Wolfe, Arthritis and Rheumatism 37(4) ;481-494, 1994.
Meade, European Heart J 16 (Suppl A); 31-35, 1995.
vander Poll, Blood 83 : 446 1994.
Hommes et al, Gastroenterology, 1995, vol. 108, No. 4, suppl., p. A838.
Leardi et al, Italian journal of surgical Sciences, 1983, vol. 13, pp. 197-201, (abstract only).
Arii et al, Circulation, 1994, vol. 90, No. 4, pat 2, p. I 522.
Vertrees et al, Asaio Journal, 1994, vol. 40, p. M554-M559.
Wakefield et al, Arteriosclerosis, Thrombosis and Vascular Biology, 1995, vol. 15, pp. 258-268.
Dhainaut et al, Critical Care Medicine, 1995, vol. 23, pp. 1461-1469. (abstract only).
Fisher et al, Critical Care Medicine, 1993, vol. 21, pp. 318-327. (abstract only).
Hooper et al, Blood, 1994, vol. 84, pp. 483-489.
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, p. 1).
Wakefield et al (Arteriosclerosis, Thrombosis and Vascular Biology, 1995, vol. 15, pp. 258-268).
Arbustini et al (American Journal of Cardiology, 1991, vol. 68,pp. B36-B50).
The abstract of Riipi et al (Infection and Immunity, 1990, vol. 58, pp. 2750-2754).
Handin, R. ‘Disorders of Coagulation and Thrombosis’, In: Harrison's Principles of Internal Medicine, 13th Ed., vol. 1, lsselbacher et al, Ed., pp. 1804-1810.
Abstract of Martini et al (Current Therapeutic Research, 1993, vol. 53, pp. 340-346).
Abstract of Di Perry et al (Haemostasis, 1986, vol. 16 Suppl. 1, pp. 42-47).
Abstracts of Mozzi et al (Haemostasis, 1986, vol. 16 Suppl. 1, pp. 36-38).
Abstract of Ciavarella et al (Haemostasis, 1986, vol. 16 Suppl. 1, pp. 39-41).
Creager et al (‘Vascular Diseases of the Extremities’, In: Harrison's Principles of Internal Medicine, 13th Ed., vol. 1, Isselbacher et al, Ed., pp. 1135-1142).
Charles et al (Journal of Immunology, 1999, vol. 163, pp. 1521-1528).
Abstract of Squadrito et al (European Journal of Pharmacology, 1993, vol. 237, pp. 223-230).
Abstract of Strieter et al (Critical Care Medicine, 1993, 21(10 suppl):S447-S463).
Elliott, M. J., et al., “Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor α,”Arthritis&Rheumatism, 36(12): 1681-1690 (1993).
Elliott, M. J., et al., “Randomised double-blind comparision of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis,”The Lancet, 344: 1105-1110 (1994).
Wolfe, F., et al., “The Mortality of Rheumatoid Arthritis,”Arthritis&Rheumatism, 37(4): 481-494 (1994).
Meade, T.W., “Fibrinogen in ischaemic heart disease,”European Heart J., 16(Suppl. A): 31-35 (1995).
Brown, A.S., and Martin, J.F., “The megakaryocyte platelet system and vascular disease,”European J. of Clinical Investigation, 24 (Suppl. 1): 9-15 (1994).
Davidsen, S.K. and Summers, J.B., “Inhibitors of TNFα Synthesis,”Exp. Opin. Ther. Patents, 5(10): 1087-1100 (1995).
Lee, J.C. et al., “Low-Molecular-Weight TNF Biosynthesis Inhibitors: Strategies and Prospectives,”Circ. Shock44:97-103 (1995).
Neuner, P. et al., “Pentoxifylline in Vivo Down-Regulates the Release of IL-1β, IL-6, IL-8 and Tumour Necrosis Factor-α by Human Peripheral Blood Mononuclear Cells,”Immunology, 83(2):262-267 (1994).
Bertini, R., et al., “Depression Of Liver Drug Metabolism And Increase In Plasma Fibrinogen By Interleukin 1 And Tumor Necrosis Factor: A Comparison With Lymphotoxin And Interferon,”Int J. Immunopharmac.(1988), 19(5):525-530.
Bertini, R., et al., “Dexamethasone modulation of in vivo effects of endotoxin, tumor necrosis factor, and interleukin-1 on liver cytochrome P-450, plasma fibrinogen and serum iron,”J. Leukoc. Biol. (1989), 46(3):254-62.
Gresser, I., et al., “Tumor necrosis factor induces acute phase proteins in rats,”Biol. Regul. Homeost. Agents(1987), 1(4):173-6.
Nawroth, P., et al., “Tumor Necrosis Factor/Cachectin-Induced Intravascular Fibrin Formation In Meth A Fibrosarcomas,”J. Exp. Med.(1988), 168:637-647.
Sekut, L., et al., “Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation,”Clin. Exp. Immunol.(1995), 100(1):126-32.
Soria, J., et al., “Pentoxifylline, fibrinogen and leukocytes,”Blood Coagul. Fibrinolysis(1990), 1(4-5):485-7.
Van Der Poll, T., et al., “Fibrinolytic Response to Tumor Necrosis Factor in Healthy Subjects,”J. Exp. Med.(1991), 174:729-732.
Van Hinsbergh, V.W., et al., “Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products,”Blood(1990), 76(11):2284-9; and.
Zabel, P. et al., “Inhibition of endogenous TNF formation by pentoxifylline,”Immunobiology(1993), 187(3-5):447-63, review.
Centocor, Inc.'s Remicade (infliximab) Products Webpage, http://www.centocor.com/cgi-in/site/products/prod—remicade.cgi (Jun. 22, 2004).
Oct. 28, 1999 Pharmacological Review for Remicade (infliximab) from the U.S. Food and Drug Administration's Center For Drug Evaluation And Research, http://www.fda.gov/cder/biologics/review/inflcen111099r2.pdf (Jun. 21, 2004).
Label and Approval History for Remicade (infliximab) from the U.S. Food and Drug Administration's Center for Evaluation And Research, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label—ApprovalHistory#apphist (Jun. 21, 2004).
Elliott Michael J.
Feldmann Marc
Maini Ravinder N.
Canella Karen A
Cooper & Dunham LLP
The Kennedy Institute of Rheumatology
White John P.
LandOfFree
Methods of preventing or treating thrombosis with tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of preventing or treating thrombosis with tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of preventing or treating thrombosis with tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4077009